-

Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured revolving credit agreement with J.P. Morgan. Subject to customary conditions, Meitheal may, at its option, request an increase in the credit facility for a total amount of up to $80 million.

“We are pleased to have closed this financing with J.P. Morgan which strengthens our balance sheet and provides us with the working capital and flexibility needed to invest in strategic areas for growth,” said CEO Tom Shea. “This transaction underscores Meitheal’s demonstrated commitment to fiscal responsibility, and we look forward to leveraging these funds to bring important, accessible medicines to patients in need.”

The three-year credit facility matures on August 9, 2026 and is secured by assets of Meitheal. Meitheal intends to use the funds for general corporate purposes.

ABOUT MEITHEAL PHARMACEUTICALS

Founded in 2017 and based in Chicago, Meitheal Pharmaceuticals is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and biosimilar products. Meitheal currently markets over 50 US Food and Drug Administration (FDA)-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of the end of June 2023, Meitheal, directly or through its partners, has over 20 products in the research and development phase, 21 products planned for launch in 2023, and an additional 20 products under review by the FDA. Meitheal’s mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers’ needs. Ranked among the top 100 Crain’s Best Places to Work in Chicago, Meitheal emulates the traditional Irish guiding principle we are named for — Meitheal (Mee·hall): working together toward a common goal, for the greater good.

Learn more about who we are and what we do at www.meithealpharma.com.

Contacts

MEDIA
Meitheal Pharmaceuticals, Inc.
John Spilman, VP of Corporate Strategy
773 889 5910
info@meithealpharma.com

Meitheal Pharmaceuticals, Inc.


Release Summary
Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan
Release Versions

Contacts

MEDIA
Meitheal Pharmaceuticals, Inc.
John Spilman, VP of Corporate Strategy
773 889 5910
info@meithealpharma.com

More News From Meitheal Pharmaceuticals, Inc.

Meitheal Pharmaceuticals Receives Approval from the US Food and Drug Administration for CONTEPO™ (fosfomycin) for injection in Patients ≥ 18 Years Having Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP)

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced approval from the U.S. Food and Drug Administration (FDA) for CONTEPO (fosfomycin) for injection for the treatment of adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible...

Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products will share new antibiotic data at the 14th annual IDWeek in Atlanta, GA, from October 19-22, 2025. Meitheal’s presentations will include clinical trial data updates on the safety and effectiveness of fosfomycin for injection for the treatment of c...

Meitheal Pharmaceuticals Announces Appointment of Dr. Keith Robinson as Chief Medical Officer and Expansion of Medical Affairs Operation

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals Announces Appointment of Dr. Keith Robinson as Chief Medical Officer and Expansion of Medical Affairs Operation...
Back to Newsroom